Navigation Links
Pharmacyclics Reports Second Quarter 2013 Results
Date:7/31/2013

th R/R CLL/SLL. This trial is a randomized, multi-center, open-label Phase III trial of ibrutinib as a monotherapy. The enrollment of 391 patients was completed more than two quarters ahead of schedule in April, 2013. The primary endpoint of this study is to demonstrate a clinically significant improvement in progression-free survival (PFS) when compared to ofatumumab. A pre-defined number of progression events will trigger an interim analysis. Pharmacyclics expects a read out from the interim analysis during Q1 of 2014. If the treatment effect of ibrutinib in comparison to ofatumumab is deemed statistically favorable by an independent review committee, a discussion with the FDA and other health authorities for a potential early filing may take place.
  • RESONATE™-17 (PCYC-1117): Phase II study of ibrutinib in a single-arm, open-label, multi-center trial using ibrutinib as a monotherapy in patients who have deletion 17p and who did not respond to or relapsed after at least one prior treatment (a high unmet need population). The primary endpoint of the study is the overall response rate (ORR). This global study has just completed enrollment more than two quarters ahead of schedule. Pharmacyclics plans to announce top-line data from this study in the first half of 2014.
  • RESONATE™-2 (PCYC-1115): Phase III study of ibrutinib versus chlorambucil in frontline newly diagnosed elderly CLL/SLL patients. This trial is a randomized, multicenter, open-label study of ibrutinib as a monotherapy versus chlorambucil in patients 65 years or older with treatment naive CLL/SLL. The study design, which was granted a Special Protocol Assessment (SPA), is designed to demonstrate superiority of ibrutinib with the primary endpoint of PFS when compared to chlorambucil. The study is currently recruiting and Pharmacyclics plans to enroll 272 patients worldwide, with an enrollment completion target by the end of Q3 of 2014.
  • HELIOS (CLL3001): Phase II
    '/>"/>

  • SOURCE Pharmacyclics, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

    Related medicine technology :

    1. Pharmacyclics Announces Date of Financial Results for Second Quarter Ended June 30, 2013 and Conference Call
    2. Pharmacyclics Reports First Quarter 2013 Results
    3. Pharmacyclics Announces Date of Financial Results for Three Months Ended March 31, 2013 and Conference Call
    4. Pharmacyclics Triggers Fourth Milestone Payment for Enrollment of 5th Patient in Frontline Phase III CLL Study
    5. Pharmacyclics Announces Third Breakthrough Therapy Designation for Ibrutinib from the U.S. Food and Drug Administration
    6. Pharmacyclics, Inc. Prices Public Offering of Common Stock
    7. Pharmacyclics, Inc. Announces Proposed Public Offering of Common Stock
    8. Pharmacyclics First to Announce Breakthrough Therapy Designation in Oncology from the U.S. Food and Drug Administration
    9. Pharmacyclics Announces Date of Financial Results for Three and Six Months Ended December 31, 2012 and Conference Call
    10. Pharmacyclics Reports Fourth Quarter and Full Year Fiscal 2012 Financial Results and Recent Developments
    11. Pharmacyclics Announces Oral Presentations of Ibrutinib (PCI-32765) at the 17th Congress of the European Hematology Association
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/11/2014)... , July 11, 2014 Research ... "Global Hypodermic Needles Market 2014-2018" report to their ... A hypodermic needle is a hollow needle commonly ... body or or to extract fluids from it. A ... or to inject substances that cannot be ingested. Hypodermic ...
    (Date:7/11/2014)... 2014 Research and Markets ( http://www.researchandmarkets.com/research/tjlw9k/immunoprotein ... "Immunoprotein Diagnostic Testing Market - Forecasts to 2019: ... 6% and is expected to be valued at ... http://photos.prnewswire.com/prnh/20130307/600769 ... been segmented according to immunoprotein types which include ...
    (Date:7/10/2014)... , 11. Juli 2014 /PRNewswire/ ... Kameras für die molekulare Bildgebung, einschließlich ... heute die CE-Zulassung für sein Navigator ... kann Dilon das Produkt jetzt europaweit ... den Großteil der europäischen Länder ausgedehnt ...
    Breaking Medicine Technology:Global Hypodermic Needles Market 2014-2018: Key Vendors are Becton, Dickinson and Co, Covidien, Retractable Technologies and Terumo Corp. 2Global Hypodermic Needles Market 2014-2018: Key Vendors are Becton, Dickinson and Co, Covidien, Retractable Technologies and Terumo Corp. 3Immunoprotein Diagnostic Testing Market - Forecasts to 2019: Expected to grow at the highest CAGR of 6% and is expected to be valued at USD 4,943.0 million 2Dilon erhält CE-Zulassung für sein Navigator-Gamma-Sondensystem 2
    ... study ... pediatric liver transplant patients, COLUMBIA, Md., Aug. 21 ... the peer-reviewed journal Liver Transplantation, have,further developed our understanding ... pediatric liver-transplant patients,post-transplantation., Working in a cooperative group ...
    ... 21 Novavax, Inc.,(Nasdaq: NVAX ) today announced ... discuss results from the Phase I/IIa human clinical,trial of ... Eastern Time on August 26, 2008., The call ... Dr. Rahul Singhvi and other members of senior management, ...
    Cached Medicine Technology:New Data Support Earlier Suggested Guidance for Levels of Cell-Mediated Immunity in Pediatric Liver Transplant Patients 2New Data Support Earlier Suggested Guidance for Levels of Cell-Mediated Immunity in Pediatric Liver Transplant Patients 3Novavax to Present Phase I/IIa Trial Data Results in an Investor Conference Call on August 26, 2008 2
    (Date:7/12/2014)... 2014 A recent article released by Seattle's ... of suggestions for those seeking cosmetic surgical procedures in ... approaching and the heat begins to enliven the rainy Pacific ... clothing, realizing that they didn’t work out as much during ... cause a sudden surge of people eager to look their ...
    (Date:7/12/2014)... Wright & Schulte LLC, an experienced law firm who ... (case #59776/2014), announces they have launched a new TV ... popular hair dye, Just For Men, has caused some men ... other areas. In addition to detailing symptoms that are allegedly ... advertisements being run by Wright & Schulte LLC will also ...
    (Date:7/12/2014)... (PRWEB) July 12, 2014 ... score of 4.1 out of 5. This above-average ... have been underpinning buyer negotiation power over the ... analyst Anna Son, “during the period, surging demand ... costs associated with new product development, have placed ...
    (Date:7/12/2014)... July 12, 2014 The largest pure ... is pleased to announce that it will be opening ... new facility will join four Atlanta-based Nova Medical Centers’ ... at 3209 Deans Bridge Road, and will be open ... , “With Nova’s treatment philosophy of rapid return-to-work ...
    (Date:7/11/2014)... Recently, MagicQuinceaneraDresses.com, the popular online supplier of special ... Quinceanera dresses . The company’s new items are ... without paying a large amount of money. They are ... , The company’s online shop has become a one ... outfits. In addition to exquisite Quinceanera dresses, it also ...
    Breaking Medicine News(10 mins):Health News:Best Summer Cosmetic Surgeries Revealed in Article By Seattle Plastic Surgeon 2Health News:Just for Men Lawsuit News: TV Campaign Launched by Wright & Schulte LLC to Inform Consumers of the Alleged Association between the Popular Hair Dye and Chemical Burns 2Health News:Just for Men Lawsuit News: TV Campaign Launched by Wright & Schulte LLC to Inform Consumers of the Alleged Association between the Popular Hair Dye and Chemical Burns 3Health News:Just for Men Lawsuit News: TV Campaign Launched by Wright & Schulte LLC to Inform Consumers of the Alleged Association between the Popular Hair Dye and Chemical Burns 4Health News:Floor-Grade Instruments Procurement Category Market Research Report from IBISWorld has Been Updated 2Health News:Floor-Grade Instruments Procurement Category Market Research Report from IBISWorld has Been Updated 3Health News:Floor-Grade Instruments Procurement Category Market Research Report from IBISWorld has Been Updated 4Health News:Nova Medical Centers To Open New Facility in Augusta, Georgia 2Health News:Cheap Quinceanera Dresses Now Available At MagicQuinceaneraDresses.com 2
    ... PolyScript(R) Labels Enable Fast and Cost-Effective CustomizationSOUTHFIELD, Mich., April ... manufactured specifically to provide equipment with safety warnings or ... to help engineering industries meet the exacting demands made ... (R) and PolyScript ...
    ... April 1 The following was released today ... Healthcare & Health IT Reporters, Editors, ... WHO: American Health Information Management Association ... Beyond Compliance to Strategic Advantage WHEN: ...
    ... Derma Sciences, Inc. ... care products, reported that sales for 2008 rose 47.1% year-over-year, ... higher sales of proprietary advanced wound care products led by ... $34.1 million in 2007. The Company,s loss increased consistent with ...
    ... The Quantum Group, Inc. (NYSE Amex: QGP ... transitioned to Continental Stock Transfer and Trust Company to act ... Quantum President & CEO, commented, "Continental Stock Transfer has been ... well regarded reputation as a comprehensive and customer-centric company that ...
    ... Alere,s groundbreaking Healthy Kids Program offers tools for ... costs estimated at $14 billion annually- Employers and ... First of its kind personalized solution that provides ... obesity and helps parents and kids become healthierMARIETTA, ...
    ... Could Save Millions on Expensive Social Services CHICAGO, ... for people who are homeless, have a mental illness, ... and cost of expensive public services such as state ... report released Thursday by the Heartland Alliance Mid-America Institute ...
    Cached Medicine News:Health News:Schreiner ProTech Introduces Intelligent Marking Solutions Achieving Process and Cost Optimizations 2Health News:Derma Sciences Reports Fourth Quarter, Year-End Results for 2008 2Health News:Derma Sciences Reports Fourth Quarter, Year-End Results for 2008 3Health News:Derma Sciences Reports Fourth Quarter, Year-End Results for 2008 4Health News:Derma Sciences Reports Fourth Quarter, Year-End Results for 2008 5Health News:Derma Sciences Reports Fourth Quarter, Year-End Results for 2008 6Health News:Derma Sciences Reports Fourth Quarter, Year-End Results for 2008 7Health News:Derma Sciences Reports Fourth Quarter, Year-End Results for 2008 8Health News:The Quantum Group Announces Transition to Continental Stock Transfer 2Health News:The Quantum Group Announces Transition to Continental Stock Transfer 3Health News:New Online Program Helps Parents Tackle Childhood Obesity 2Health News:New Online Program Helps Parents Tackle Childhood Obesity 3Health News:Study Links Reduced Use of Mental Health Facilities, Nursing Homes and Other Public Services to "Smart Investments" in Supportive Housing 2Health News:Study Links Reduced Use of Mental Health Facilities, Nursing Homes and Other Public Services to "Smart Investments" in Supportive Housing 3Health News:Study Links Reduced Use of Mental Health Facilities, Nursing Homes and Other Public Services to "Smart Investments" in Supportive Housing 4Health News:Study Links Reduced Use of Mental Health Facilities, Nursing Homes and Other Public Services to "Smart Investments" in Supportive Housing 5
    ... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
    ... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
    ... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
    ... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
    Medicine Products: